SCM
CLDX icon

Stevens Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Stevens Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,118
Closed -$412K – 1033
2014
Q3 		$412K Buy
+2,118
New +$461K 0.01% 639

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stevens Capital Management's CLDX Position: Q4 2014 in Review

Stevens Capital Management sold out of Celldex Therapeutics (CLDX) in Q4 2014, closing a stake of 2,118 shares — an estimated $412K sold.

Stevens Capital Management first reported a position in CLDX in Q3 2014 and held it in 1 quarter. The position peaked at $412K in Q3 2014. 163 funds tracked by Wall St. Rank hold CLDX as of Q4 2014.

  • Stevens Capital Management reported no remaining Celldex Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Stevens Capital Management sold 2,118 Celldex Therapeutics shares in Q4 2014, an estimated $412K.
  • Stevens Capital Management first reported a position in Celldex Therapeutics in Q3 2014 and held it in 1 quarter.
  • Stevens Capital Management's Celldex Therapeutics position peaked at $412K in Q3 2014.
  • 163 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2014.

Based on Stevens Capital Management's 13F filing for Q4 2014, filed 10 Feb 2015.